Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States

被引：0
|
作者：
Weiting Liao
Wanting Lei
Mingyang Feng
Yang Yang
Qiuji Wu
Kexun Zhou
Liangliang Bai
Feng Wen
Qiu Li
机构：
[1] Sichuan University,Department of Medical Oncology, Cancer Center, West China Hospital
[2] Sichuan University,West China Biomedical Big Data Center
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Cost-effectiveness; Anti-angiogenesis; Immunotherapy; Cabozantinib; Nivolumab; Renal cell carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5662 / 5670
页数：8
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States
    Liao, Weiting
    Lei, Wanting
    Feng, Mingyang
    Yang, Yang
    Wu, Qiuji
    Zhou, Kexun
    Bai, Liangliang
    Wen, Feng
    Li, Qiu
    [J]. ADVANCES IN THERAPY, 2021, 38 (12) : 5662 - 5670
  • [2] Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [3] Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma
    Liu, Ruizhe
    Qiu, Kaifeng
    Wu, Junyan
    Jiang, Yanqing
    Wu, Peihao
    Pang, Jianxin
    [J]. IMMUNOTHERAPY, 2022, 14 (11) : 859 - 869
  • [4] Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma
    Liu, Tong
    Jin, Yao
    Dong, Mei
    [J]. CLINICAL GENITOURINARY CANCER, 2023, 21 (06) : E449 - E460
  • [5] COST EFFECTIVENESS OF CABOZANTINIB PLUS NIVOLUMAB AS FIRST-LINE TREATMENT FOR RENAL CELL CARCINOMA
    Marciniak, A.
    Gultyaev, D.
    Orbzut, G.
    Mollon, P.
    Wallace, J. F.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S300 - S301
  • [6] Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
    Wu, Bin
    Zhang, Qiang
    Sun, Jie
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [7] Advanced Renal Cell Carcinoma Cabozantinib plus Nivolumab: New First-Line Standard?
    Schmale, Ine
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 362 - 363
  • [8] COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS
    Klijn, S.
    Van de Wetering, G.
    Malcolm, B.
    Dale, P.
    Pompen, M.
    Stevanovic, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S46 - S46
  • [9] Cost-effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan
    Maeda, Tomomi
    Moriwaki, Kensuke
    Morimoto, Kosuke
    Yoshioka, Takashi
    Goto, Rei
    Shimozuma, Kojiro
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2024, 40 : 118 - 126
  • [10] Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma
    Vitale, Maria Giuseppa
    Nasso, Cecilia
    Oltrecolli, Marco
    Baldessari, Cinzia
    Fanelli, Martina
    Dominici, Massimo
    Sabbatini, Roberto
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1183 - 1192
12345